Truveta

Truveta — Health-system-derived clinical real-world data: de-identified longitudinal records contributed by a consortium of major US health systems, described as 85+ health data points per patient spanning full electronic medical records, diagnostic and laboratory results, medications and prescriptions, clinical notes, claims, mortality linkage and social drivers of health, refreshed daily. The specific asset surfaced here is the GLP-1 receptor-agonist prescribing surveillance built on it: 3.54 million patients across 18.52 million prescriptions from January 2019 to June 2026, split by FDA-la…

Truveta offers (Alternative, Fundamental, Reference) — Stated in the published surveillance: 3.54 million patients and 18.52 million GLP-1 prescriptions over the 2019-2026 window, drawn from a dataset described as 85+ health data points per patient with daily updates — implying a corpus on the order of billions of clinical and claims events across a consortium population in the tens of millions.

GLP-1 and obesity-drug launch tracking and uptake forecasting, market-share and first-prescriber dynamics by agent and indication, real-world tolerability and discontinuation analysis with clinical context, label-expansion and new-market-entry impact assessment, comparative-effectiveness studies using lab-anchored outcomes, cardiometabolic and liver-disease cohort discovery, health-system quality and population-health analytics, treatment-pattern benchmarking for payer and provider contracting, and model training on longitudinal clinical progression with hard endpoints

The data is with 7 years of history.

Coverage spans US; Health Care Technology, Pharmaceuticals; alternative, fundamental, reference; equities.

The supplier's own access route is a contact form. Request a sample through Brickroad to start.